- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Officials at NanCogenics announced today that Co-Founder and Professor of Molecular and Cellular Oncology at the University of Texas M D Anderson Cancer Center, Jim Klostergaard, has accepted an invitation to present a Keynote Forum address at the 3rd International Conference on Nanotek and Expo, being held in Las Vegas, NV, December 2 - 4. Dr. Klostergaard's lecture is titled, The Magnetic Localization of Drug-Loaded Nanoparticles for Tumor Therapy: Pre-Clinical Validation.
The OMICS Nanotek 2013 Conference and Exposition brings together an international group of scientists and business development experts across the range of pharmaceutical, health care, food technology, biotech & diagnostic industries and academia, in an effort to create a forum for the assessment and evaluation of emerging technologies across the globe. Nanotek provides a perfect platform for scientists, engineers, directors of companies and students in the field of Nanotechnology to meet and share their knowledge, paving a way for visionaries gather and put forward many thought provoking strategies.
NanCogenics is a nanobiotechnology venture that has validated, in pre-clinical studies, a technology platform for the tumor-specific targeting of therapeutics for the treatment of cancer, focusing initially on a clinical procedure for breast cancer. The proprietary platform delivers, through systemic administration, chemotherapeutic pro-drug constructs to the tumor micro-environment, generating effective anti-tumor results without harm to normal tissue or organs. The Co-Founders believe that the advancement of this platform to the clinic will lead to significant improvements in localized cancer chemotherapy, while also providing a localization platform for a range of new therapeutics now under development.
The Company is now advancing the technology platform on an initial clinical path as a treatment modality for breast cancers. As noted by Dr. Klostergaard, “There is an emerging realization that despite much effort, the prevailing approach to development of targeted therapeutics has yielded too few clinical successes, and that the plasticity of tumors and the range of their mutations may undermine the basis for targeting individual signaling pathways.” Dr. Klostergaard further points out that the NanCogenics approach adds a biophysical targeting component for localized delivery, intended to advance drug targeting technology significantly beyond conventional targeting methodologies.
The Co-Founders of NanCogenics see the Company as a resource for enhanced and improved therapeutic performance, delivering higher concentrations of drug to the target site, with less to healthy tissue. The capacity to localize cytotoxic drugs in high concentrations will lead to more effective treatment regimens, greater patient compliance to therapy and improved outcomes, such as patient quality of life and survival rates. The compactness and modular design of the Magnetic Localization Unit also presents a mobility feature, offering a capability to reach under-served populations, in addition to treatment centers within established healthcare facilities.
Safe Harbor Statement
Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.
For more information, please click here
5000 Montrose Blvd, Unit 10A
Houston, TX 77006
Copyright © NanCogenicsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016